Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
iTeos Therapeutics ( (ITOS) ) has shared an update.
On June 1, 2025, Tim Van Hauwermeiren resigned from the Board of Directors of iTeos Therapeutics, Inc., effective immediately. His resignation was not due to any disagreements with the company, its management, or the board, indicating a smooth transition without internal conflict.
The most recent analyst rating on (ITOS) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on iTeos Therapeutics stock, see the ITOS Stock Forecast page.
Spark’s Take on ITOS Stock
According to Spark, TipRanks’ AI Analyst, ITOS is a Neutral.
iTeos Therapeutics is facing considerable financial difficulties with declining profitability and cash flow issues. Despite some technical momentum, overbought signals and negative corporate events such as the strategic wind down and termination of a major collaboration weigh heavily on the stock’s outlook. The negative P/E ratio and absence of dividends further challenge its valuation.
To see Spark’s full report on ITOS stock, click here.
More about iTeos Therapeutics
Average Trading Volume: 1,181,910
Technical Sentiment Signal: Hold
Current Market Cap: $386.6M
See more insights into ITOS stock on TipRanks’ Stock Analysis page.